Available from: www.prnewswire.com/news-releases/semaglutide-2-4-mg-injection-demonstrated-significant-weight-loss-versus-placebo-when-added-to-intensive-behavioral-therapy-301167230.html (Accessed on: Nov 05, 2020)
Choosing semaglutide GLP-1 for effective weight management offers a clinically proven solution to help reduce appetite and promote sustainable weight loss
No immunological benefit of selenium in consecutive patients with autoimmune thyroiditis
The FLOW trial demonstrated that semaglutide significantly reduces the risk of major kidney endpoints in patients with type 2 diabetes and chronic kidney disease, irrespective of baseline cardiovascular status
It was brought to market so fast that the manufacturer faced fines for breaching the Association of the British Pharmaceutical Industry's Code of Conduct because they promoted it before it was granted approval to be marketed
Characteristics of PCD include low carnitine levels in the blood, reduced carnitine reserves within cells, and an increase in carnitine loss through the urine